ED
PTRA

Exane Derivatives’s Proterra Inc. Common Stock PTRA Stock Holding History

Exane Derivatives’s Portfolio PTRA Stock Details PTRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-102,307
Closed -$1.13M – 972
2020
Q4 		$1.13M Buy
+102,307
New +$1.07M 0.33% 70

Other funds holding PTRA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GCM
Graham Capital Management Rowayton, Connecticut $4.14B AUM 17.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
YCM
Yaupon Capital Management New York $3.2B AUM 46.52% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Exane Derivatives's PTRA Position: Q1 2021 in Review

Exane Derivatives sold out of Proterra Inc. Common Stock (PTRA) in Q1 2021, closing a stake of 102,307 shares — an estimated $1.13M sold.

Exane Derivatives first reported a position in PTRA in Q4 2020 and held it in 1 quarter. The position peaked at $1.13M in Q4 2020. 47 funds tracked by Wall St. Rank hold PTRA as of Q1 2021.

  • Exane Derivatives reported no remaining Proterra Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Exane Derivatives sold 102,307 Proterra Inc. Common Stock shares in Q1 2021, an estimated $1.13M.
  • Exane Derivatives first reported a position in Proterra Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Exane Derivatives's Proterra Inc. Common Stock position peaked at $1.13M in Q4 2020.
  • 47 funds tracked by Wall St. Rank held Proterra Inc. Common Stock as of Q1 2021.

Based on Exane Derivatives's 13F filing for Q1 2021, filed 30 Apr 2021.